MAHON PAUL A sold $4.3M of UTHR
MAHON PAUL A (EVP & GENERAL COUNSEL) sold 8,300 shares of UNITED THERAPEUTICS Corp (UTHR) at an average of $517.05 ($512.92–$522.40, $4.29M total) across 8 trades on 2026-08-06 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest fact is the specific insider sale details: 8,300 shares sold on 2026-08-06 at a weighted average price of $517.0497, totaling about $4.29M, under a pre-arranged 10b5-1 plan.
Market read
Traders may monitor insider activity for sentiment, but a 10b5-1 plan sale is usually not a standalone fundamental catalyst.
What to watch
The article does not state whether other insiders sold/bought around the same time, nor does it provide context on compensation, tax obligations, or diversification needs.
Background
The article is a SEC Form 4 insider transaction disclosure for United Therapeutics (UTHR).
Ticker impact
United Therapeutics Form 4 shows EVP and General Counsel Paul A. Mahon sold 8,300 shares on 2026-08-06 under a 10b5-1 plan.
Limited near-term impact expected; any reaction is likely sentiment-driven rather than fundamental.
The filing discloses the sale size, price range, and that it was executed under a pre-arranged 10b5-1 plan, reducing interpretive weight versus non-plan sales.
Market effects
No direct sector read-through; this is company-specific insider transaction disclosure.
None.
None.
Counterpoint
Even with a 10b5-1 plan, repeated insider selling can still be interpreted by some traders as a mild negative sentiment signal.
Key entities
- issuerUNITED THERAPEUTICS Corp
Company whose insider transaction was disclosed via SEC Form 4.
- insiderMAHON PAUL A
EVP & General Counsel who sold shares on 2026-08-06.
